Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The Global Spinal Muscular Atrophy (SMA) Market, by Disease Type (Type I, Type II, Type III, and Type IV), By Treatment (Gene Therapy and Drugs), by Age (Infant and Adult), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was estimated to be valued at US$ 884 million in 2017 and is estimated to exhibit a CAGR of 12.4% over the forecast period (2018-2026). Spinal muscular atrophy market is expected to witness significant growth over the forecast period, owing to increasing number of clinical trials by key players to develop effective treatment for the disease.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/1920
Increasing focus on clinical trials is expected to drive growth of the spinal muscular atrophy (SMA) market
The increasing number of clinical trials conducted by key players, coupled with rising government support for these clinical trials are factors that are expected to propel growth of the spinal muscular atrophy market over the forecast period. Various clinical studies focus on therapeutic strategies to increase survival motor neuron (SMN) protein in motor neurons since these neurons control muscle movement in the body. SMN protein is important for maintenance of motor neurons, which are found in the spinal cord and brainstem, the part of the brain that is connected to the spinal cord.
Currently, Spinraza is the only one approved drug that is available for the treatment of spinal muscular atrophy. For instance, in 2016, the U.S. FDA approved Spinraza (nusinersen) drug from Biogen for the treatment of SMA. Spinraza targets the underlying defect in SMA, so it can help prevent, delay, or even reverse the symptoms. However, its common side effects include higher risk of constipation and respiratory tract infection, coupled with minimal risk of kidney problems and bleeding, which is expected to hamper the market growth.
Several biotechnology and biopharmaceutical players are engaged on developing effective treatment for SMA. For instance, AveXis received the FDA approval for manufacturing of AVXS-101 gene therapy, in 2017. It is currently in development stage, and has been granted Orphan Drug Designation in 2017 for the treatment of all types of spinal muscular atrophy (SMA) and Breakthrough Therapy Designation in 2016 for the same. It also received Fast Track Designation in 2016, for the treatment of SMA Type 1, one of the most chronic neurological genetic disorders.
Similarly, in April 2018, AveXis initiated a Phase 3 trial, for STR1VE in infants with SMA type 1. AveXis also plans to initiate a similar trial in Europe called STR1VE EU.
Browse 32 Market Data Tables and 26 Figures spread through 161 Pages and in-depth TOC on “Spinal Muscular Atrophy Market, by Disease Type (Type I, Type II, Type III, Type IV), By Treatment (Gene Therapy and Drugs), by Age (Infant and Adult), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2026”
To know the latest trends and insights prevalent in the spinal muscular atrophy market Press Release, click the link below: https://bit.ly/2ZOd5SI
Additionally, key players are focusing on mergers and acquisitions, new product launches, and partnerships, in order to strengthen their position in the global market. For instance, in 2016, Ionis discovered Spinraza and co-developed the drug with Biogen. Moreover, Ionis received a payment of US$ 320 million from Biogen for the development of Spinraza till the year 2016, including US$ 90 million based on regulatory approvals in Japan and Europe. Moreover, in 2015, Roche acquired Trophos with an intent of continuing clinical trials for Olesoxime. The company is currently planning a Phase 3 study enrolling individuals with SMA type II or III.
Key Takeaways of the Spinal Muscular Atrophy Market:
- The global spinal muscular atrophy market is expected to exhibit a CAGR of 12.4% over the forecast period, attributed to rising number of clinical trials for development of new therapies
- Among treatment, drugs segment held a dominant position in the spinal muscular atrophy market in 2017, owing to approval of single drug Spinraza
- Among disease type, type I segment held a dominant position in the spinal muscular atrophy market in 2017. This is attributed for being the most common and severe form of SMA. For instance, according to SMA Europe 2015 data, type I accounts for 50% to 70% of cases of childhood onset SMA.
- Among regions, North America held a dominant position in 2017 attributed to high demand for spinal muscular atrophy treatment as a result of higher diagnosis rate in the region.
- Key players operating in the global spinal muscular atrophy market include Biogen, Cytokinetics, Inc., F. Hoffmann-La Roche, Novartis AG, Pfizer, and Ionis Pharmaceuticals, Inc.
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1920
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027